“We have an incredibly powerful, incredibly productive research and development program being run by N.I.H.,” Ameet Sarpatwari, an instructor at Harvard Medical School, said. “Taxpayers put in money that is paying big dividends, and yet we pay higher prices for prescription drugs than any other country. In effect, we have taxpayers paying twice.”
WASHINGTON, DC — Patients For Affordable Drugs' Executive Director, Ben Wakana, issued the following statement regarding the news that PhRMA, the pharmaceutical industry’s main trade organization, broke a record for money spent lobbying in the first quarter of 2018.
“Drug corporations are running scared. The public knows the truth about America’s rigged prescription drug pricing system, so PhRMA is doing what PhRMA does best, lobbying lawmakers behind closed doors. Patients are demanding lower drug prices, and in response, PhRMA fattened its lobbying budget, revealing the industry’s true priorities.”